All In Biotech

Drug Trial Radar · NCT04851964

Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT)

Last checked: Nov 20, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

416

Actual

Start

Apr 22, 2021

Primary completion

Sep 23, 2024

Study completion Dec 11, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Amgen
First posted
Apr 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps

Interventions

  • Experimental: TezepelumabBiological

    Tezepelumab subcutaneous injection

  • PlaceboOther

    Placebo subcutaneous injection

  • Mometasone furoate or equivalent intranasal corticosteroidDrug

    Background MFNS or equivalent INCS at stable dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Total Nasal Polyp Score at Week 52Time frame: Baseline to Week 52
  2. Change From Baseline in Bi-weekly Mean Nasal Congestion Score (NCS) at Week 52Time frame: Baseline to Week 52

Locations

112 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Bakersfield, California

  • Research Site

    Newport Beach, California

  • Research Site

    Roseville, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Boca Raton, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Baltimore, Maryland

  • Research Site

    White Marsh, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Columbia, Missouri

  • Research Site

    New York, New York

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    North Charleston, South Carolina

  • Research Site

    Dallas, Texas

  • Research Site

    Norfolk, Virginia

  • Research Site

    Spokane, Washington

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Hamilton, Ontario, Canada

  • Research Site

    London, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Trois-Rivières, Quebec, Canada

  • Research Site

    Bengbu, China

  • Research Site

    Chengdu, China

  • Research Site

    Guangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hengyang, China

  • Research Site

    Lanzhou, China

  • Research Site

    Nanchang, China

  • Research Site

    Nanjing, China

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.